Atara Biotherapeutics, Inc. (ATRA) Given Consensus Recommendation of “Hold” by Analysts
Shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) have been given a consensus rating of “Hold” by the seven research firms that are presently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $25.75.
Several equities research analysts have recently issued reports on ATRA shares. Canaccord Genuity reiterated a “buy” rating and set a $47.00 price objective on shares of Atara Biotherapeutics in a research report on Friday, April 21st. Jefferies Group LLC reiterated a “buy” rating and set a $30.00 price objective on shares of Atara Biotherapeutics in a research report on Thursday, June 22nd. Zacks Investment Research upgraded shares of Atara Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 27th. William Blair reiterated an “outperform” rating on shares of Atara Biotherapeutics in a research report on Monday, June 26th. Finally, ValuEngine cut shares of Atara Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 1st.
In related news, EVP Christopher Haqq sold 6,000 shares of the business’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $12.65, for a total value of $75,900.00. Following the sale, the executive vice president now owns 368,080 shares in the company, valued at $4,656,212. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Isaac E. Ciechanover sold 6,900 shares of the business’s stock in a transaction on Wednesday, May 31st. The stock was sold at an average price of $13.35, for a total transaction of $92,115.00. Following the completion of the sale, the chief executive officer now owns 731,859 shares in the company, valued at approximately $9,770,317.65. The disclosure for this sale can be found here. Insiders sold 40,850 shares of company stock worth $591,296 in the last 90 days. 16.10% of the stock is currently owned by company insiders.
A number of large investors have recently made changes to their positions in the company. State Street Corp boosted its stake in shares of Atara Biotherapeutics by 62.8% in the fourth quarter. State Street Corp now owns 600,521 shares of the biotechnology company’s stock valued at $8,526,000 after buying an additional 231,541 shares in the last quarter. Norges Bank purchased a new position in Atara Biotherapeutics during the fourth quarter worth $4,031,000. Teachers Advisors LLC boosted its position in Atara Biotherapeutics by 5.5% in the fourth quarter. Teachers Advisors LLC now owns 137,416 shares of the biotechnology company’s stock worth $1,951,000 after buying an additional 7,165 shares during the period. Wells Fargo & Company MN boosted its position in Atara Biotherapeutics by 9.0% in the first quarter. Wells Fargo & Company MN now owns 58,252 shares of the biotechnology company’s stock worth $1,197,000 after buying an additional 4,791 shares during the period. Finally, Jennison Associates LLC purchased a new position in Atara Biotherapeutics during the first quarter worth $829,000. Institutional investors own 78.21% of the company’s stock.
Shares of Atara Biotherapeutics (ATRA) traded down 3.34% during midday trading on Tuesday, hitting $14.45. 83,126 shares of the stock were exchanged. Atara Biotherapeutics has a 1-year low of $11.80 and a 1-year high of $23.40. The firm has a 50-day moving average of $15.04 and a 200-day moving average of $15.93. The company’s market capitalization is $441.58 million.
Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by $0.05. On average, equities analysts expect that Atara Biotherapeutics will post ($3.88) EPS for the current year.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.